Skip to main content
Grant Details

Grant Number: 5R03CA137799-02 Interpret this number
Primary Investigator: Stanford, Janet
Organization: Fred Hutchinson Cancer Research Center
Project Title: Estrogen Pathway Genes and Association with Prostate Cancer Risk
Fiscal Year: 2009
Back to top


Abstract

DESCRIPTION (provided by applicant): Prostate cancer (PCa) is a major public health concern for which the substantial morbidity and mortality burden on society is expected to grow with the aging baby boom generation. The carcinogenic effects of estrogen on the prostate have been clearly demonstrated in animal, cell line, and tissue expression studies. Paradoxically, there is a current resurgence of interest in using synthetic estrogens to treat patients with advanced PCa. The dual effect of estrogen appears to be receptor mediated and dependant on steroid pathway interactions. This study will investigate PCa risk and germline genetic variation in genes encoding the estrogen receptors subtypes ESR1 (ESR1) and ESR2 (ESR2), the gene encoding aromatase (CYP19A1) that converts testosterone to estrogen, and the genes that encode estrogen catabolism enzymes (CYP1A1 and CYP1B1). We propose the following primary aims: 1) To comprehensively genotype ESR1, ESR2, CYP19A1, CYP1A1 and CYP1B1 using tag single nucleotide polymorphisms (SNPs) in a population-based case-control study of PCa and estimate relative risks associated with individual SNPs, haplotypes, and within multigenic pathways. 2) To evaluate genotypes association with PCa risk according to measures of disease aggressiveness. We also propose the following secondary aims: (1) To examine obesity as a possible effect modifier in genotype associations with overall PCa risk; (2) To determine whether genotypes are associated with adverse patient outcomes by calculating risk of PCa recurrence/progression and mortality; (3) To measure ESR1 and ESR2 gene expression in solid tumor tissue samples taken from cases undergoing radical prostatectomy and correlate these findings with ESR1 and ESR2 genotypes; and, (4) To investigate associations of genotypes with patient outcomes among men treated with androgen deprivation therapy. To accomplish these aims, we will to build upon an existing population-based study of 1,457 histologically confirmed PCa cases and 1,351 age-frequency matched controls without a history of PCa. The SNPs will be selected using publicly available data to comprehensively cover common haplotype variation within each gene. Prostate cancer risk will be estimated using adjusted unconditional logistic and polytomous regression. Risk of disease recurrence/progression and prostate-specific cancer mortality will be estimated using Cox proportional hazards (PH) regression. Results from this study may provide novel information on how estrogen pathway genes alter risk of PCa and, more importantly, who may be at risk for more aggressive forms of the disease. In addition, this study may identify patient characteristics that interplay with genotypes to increase risk. Lastly, results may serve as pilot data to further explore novel estrogen or anti-estrogen therapeutic approaches.

Back to top


Publications

Quantitative comparison and reproducibility of pathologist scoring and digital image analysis of estrogen receptor β2 immunohistochemistry in prostate cancer.
Authors: Rizzardi A.E. , Zhang X. , Vogel R.I. , Kolb S. , Geybels M.S. , Leung Y.K. , Henriksen J.C. , Ho S.M. , Kwak J. , Stanford J.L. , et al. .
Source: Diagnostic pathology, 2016-07-11; 11(1), p. 63.
EPub date: 2016-07-11.
PMID: 27401406
Related Citations

Prostate Cancer Expression Profiles of Cytoplasmic ERβ1 and Nuclear ERβ2 are Associated with Poor Outcomes following Radical Prostatectomy.
Authors: Schade G.R. , Holt S.K. , Zhang X. , Song D. , Wright J.L. , Zhao S. , Kolb S. , Lam H.M. , Levin L. , Leung Y.K. , et al. .
Source: The Journal of urology, 2016 06; 195(6), p. 1760-6.
EPub date: 2016-01-22.
PMID: 26804755
Related Citations

Variation in selenoenzyme genes and prostate cancer risk and survival.
Authors: Geybels M.S. , Hutter C.M. , Kwon E.M. , Ostrander E.A. , Fu R. , Feng Z. , Stanford J.L. , Peters U. .
Source: The Prostate, 2013 May; 73(7), p. 734-42.
EPub date: 2012-11-09.
PMID: 23143801
Related Citations

Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression.
Authors: FitzGerald L.M. , Zhang X. , Kolb S. , Kwon E.M. , Liew Y.C. , Hurtado-Coll A. , Knudsen B.S. , Ostrander E.A. , Stanford J.L. .
Source: Human mutation, 2013 Jan; 34(1), p. 149-56.
EPub date: 2012-10-04.
PMID: 22887727
Related Citations

Association of variants in estrogen-related pathway genes with prostate cancer risk.
Authors: Holt S.K. , Kwon E.M. , Fu R. , Kolb S. , Feng Z. , Ostrander E.A. , Stanford J.L. .
Source: The Prostate, 2013 Jan; 73(1), p. 1-10.
EPub date: 2012-05-01.
PMID: 22549291
Related Citations

Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.
Authors: Lin D.W. , FitzGerald L.M. , Fu R. , Kwon E.M. , Zheng S.L. , Kolb S. , Wiklund F. , Stattin P. , Isaacs W.B. , Xu J. , et al. .
Source: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2011 Sep; 20(9), p. 1928-36.
EPub date: 2011-08-16.
PMID: 21846818
Related Citations

Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer.
Authors: FitzGerald L.M. , Kwon E.M. , Conomos M.P. , Kolb S. , Holt S.K. , Levine D. , Feng Z. , Ostrander E.A. , Stanford J.L. .
Source: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2011 Jun; 20(6), p. 1196-203.
EPub date: 2011-04-05.
PMID: 21467234
Related Citations




Back to Top